Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 7 sources
Single 25 mg dose in COMP005 and two fixed doses in COMP006
Dose response in the phase 2b trial
Retreatment in Parts B and C of the phase 3 trials
Dosing the company intends to seek in labeling
Capsule strength and count in the phase 1 study
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote